Editas Medicine, Inc. (NASDAQ:EDIT) Receives $13.90 Average Price Target from Analysts

Shares of Editas Medicine, Inc. (NASDAQ:EDIT – Get Free Report) have been given an average rating of “Moderate Buy” by the ten brokerages that are presently covering the firm, MarketBeat.com reports. Five research analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1-year […]

Related Keywords

China ,Baisong Mei ,Jessica Hopfield ,Jpmorgan Chase Co ,International Assets Investment Management ,Nasdaq ,Capital Management Inc ,China Universal Asset Management Co ,Morgan Stanley ,Barclays ,Citigroup Inc ,Citigroup ,Securities Exchange Commission ,Vanguard Group Inc ,Editas Medicine Company Profile ,Editas Medicine Inc ,Editas Medicine ,Get Free Report ,Exchange Commission ,Director Jessica Hopfield ,Assets Investment Management ,China Universal Asset Management ,Universal Asset Management ,Get Free ,Leber Congenital Amaurosis ,Editas Medicine Daily ,